Literature DB >> 22789393

Muscle specific kinase autoantibodies cause synaptic failure through progressive wastage of postsynaptic acetylcholine receptors.

Marco Morsch1, Stephen W Reddel, Nazanin Ghazanfari, Klaus V Toyka, William D Phillips.   

Abstract

In myasthenia gravis muscle weakness is caused by autoantibodies against components of the neuromuscular junction. Patient autoantibodies against muscle specific kinase (MuSK) deplete MuSK from the postsynaptic membrane and reproduce signs of myasthenia gravis when injected into mice. Here we have examined the time-course of structural and functional changes that lead up to synaptic failure. C57Bl6J mice received daily injections of anti-MuSK patient IgG for 15 days. Mice began to lose weight from day 12 and demonstrated whole-body weakness by day 14. Electromyography indicated synaptic impairment from day 6 in the gastrocnemius muscle and from day 10 in the diaphragm muscle. Confocal microscopy revealed linear declines in the area and density of postsynaptic acetylcholine receptors (3-5% per day) from day 1 through day 15 of the injection series in all five muscles examined. Intracellular recordings from the diaphragm muscle revealed comparable progressive declines in the amplitude of the endplate potential and miniature endplate potential of 3-4% per day. Neither quantal content nor the postsynaptic action potential threshold changed significantly over the injection series. The inverse relationship between the quantal amplitude of a synapse and its quantal content disappeared only late in the injection series (day 10). Our results suggest that the primary myasthenogenic action of anti-MuSK IgG is to cause wastage of postsynaptic acetylcholine receptor density. Consequent reductions in endplate potential amplitudes culminated in failure of neuromuscular transmission.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22789393     DOI: 10.1016/j.expneurol.2012.06.034

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  19 in total

1.  Muscle-specific kinase (MuSK) autoantibodies suppress the MuSK pathway and ACh receptor retention at the mouse neuromuscular junction.

Authors:  Nazanin Ghazanfari; Marco Morsch; Stephen W Reddel; Simon X Liang; William D Phillips
Journal:  J Physiol       Date:  2014-05-23       Impact factor: 5.182

2.  The neuromuscular junction: measuring synapse size, fragmentation and changes in synaptic protein density using confocal fluorescence microscopy.

Authors:  Nigel Tse; Marco Morsch; Nazanin Ghazanfari; Louise Cole; Archunan Visvanathan; Catherine Leamey; William D Phillips
Journal:  J Vis Exp       Date:  2014-12-26       Impact factor: 1.355

Review 3.  The role of muscle-specific tyrosine kinase (MuSK) and mystery of MuSK myasthenia gravis.

Authors:  Inga Koneczny; Judith Cossins; Angela Vincent
Journal:  J Anat       Date:  2013-03-04       Impact factor: 2.610

4.  Pyridostigmine but not 3,4-diaminopyridine exacerbates ACh receptor loss and myasthenia induced in mice by muscle-specific kinase autoantibody.

Authors:  Marco Morsch; Stephen W Reddel; Nazanin Ghazanfari; Klaus V Toyka; William D Phillips
Journal:  J Physiol       Date:  2013-02-25       Impact factor: 5.182

5.  Effects of electroacupuncture on recovery of the electrophysiological properties of the rabbit gastrocnemius after contusion: an in vivo animal study.

Authors:  Shouyao Liu; Rongguo Wang; Dan Luo; Qianwei Xu; Cheng Xiao; Peng Lin; Zhange Yu; Xuanji Zhao; Rongrong Cai; Jinhui Ma; Qingxi Zhang; Yunting Wang
Journal:  BMC Complement Altern Med       Date:  2015-03-19       Impact factor: 3.659

6.  Effects of the ß2-adrenoceptor agonist, albuterol, in a mouse model of anti-MuSK myasthenia gravis.

Authors:  Nazanin Ghazanfari; Marco Morsch; Nigel Tse; Stephen W Reddel; William D Phillips
Journal:  PLoS One       Date:  2014-02-05       Impact factor: 3.240

7.  Altered active zones, vesicle pools, nerve terminal conductivity, and morphology during experimental MuSK myasthenia gravis.

Authors:  Vishwendra Patel; Anne Oh; Antanina Voit; Lester G Sultatos; Gopal J Babu; Brenda A Wilson; Mengfei Ho; Joseph J McArdle
Journal:  PLoS One       Date:  2014-12-01       Impact factor: 3.240

Review 8.  Multiple MuSK signaling pathways and the aging neuromuscular junction.

Authors:  Lauren A Fish; Justin R Fallon
Journal:  Neurosci Lett       Date:  2020-04-28       Impact factor: 3.046

9.  Sequence of age-associated changes to the mouse neuromuscular junction and the protective effects of voluntary exercise.

Authors:  Anson Cheng; Marco Morsch; Yui Murata; Nazanin Ghazanfari; Stephen W Reddel; William D Phillips
Journal:  PLoS One       Date:  2013-07-03       Impact factor: 3.240

10.  Dystrophin restoration therapy improves both the reduced excitability and the force drop induced by lengthening contractions in dystrophic mdx skeletal muscle.

Authors:  Pauline Roy; Fredérique Rau; Julien Ochala; Julien Messéant; Bodvael Fraysse; Jeanne Lainé; Onnik Agbulut; Gillian Butler-Browne; Denis Furling; Arnaud Ferry
Journal:  Skelet Muscle       Date:  2016-07-20       Impact factor: 4.912

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.